Research ArticleHIV

Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection

+ See all authors and affiliations

Science Translational Medicine  09 Aug 2017:
Vol. 9, Issue 402, eaaf1483
DOI: 10.1126/scitranslmed.aaf1483

Article Information

vol. 9 no. 402

Print ISSN: 
Online ISSN: 
History: 
  • Received for publication December 23, 2015
  • Resubmitted December 8, 2016
  • Accepted for publication May 9, 2017

Author Information

  1. Matthew S. Parsons1,*,
  2. Sarah B. Lloyd1,
  3. Wen Shi Lee1,
  4. Anne B. Kristensen1,
  5. Thakshila Amarasena1,
  6. Rob J. Center1,2,
  7. Brandon F. Keele3,
  8. Jeffrey D. Lifson3,
  9. Celia C. LaBranche4,
  10. David Montefiori4,
  11. Bruce D. Wines2,
  12. P. Mark Hogarth2,
  13. Kristine M. Swiderek5,
  14. Vanessa Venturi6,
  15. Miles P. Davenport6 and
  16. Stephen J. Kent1,7,8,*
  1. 1Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria 3000, Australia.
  2. 2Centre for Biomedical Research, Burnet Institute, Melbourne, Victoria 3004, Australia.
  3. 3AIDS and Cancer Virus Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
  4. 4Department of Surgery, Duke University, Durham, NC 27710, USA.
  5. 5Theraclone Sciences Inc., Seattle, WA 98104, USA.
  6. 6Kirby Institute for Infection and Immunity, University of New South Wales, Sydney, New South Wales 2052, Australia.
  7. 7Melbourne Sexual Health Centre, Alfred Hospital Department of Infectious Diseases, Central Clinical School, Monash University, Melbourne, Victoria 3053, Australia.
  8. 8Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Parkville, Victoria 3052, Australia.
  1. *Corresponding author. Email: skent{at}unimelb.edu.au (S.J.K.); mattp{at}unimelb.edu.au (M.S.P.)

AltMetrics

Article usage

AbstractFullPDF
Aug 20173320119196